Dimensional Fund Advisors LP Raises Holdings in Ironwood Pharmaceuticals, Inc. $IRWD

Key Points

• Dimensional Fund Advisors increased its Ironwood Pharmaceuticals stake by 529.3% in the first quarter, acquiring 1.75 million additional shares and bringing its ownership to 2.08 million shares, or 1.28% of the company.
• Ironwood insiders recently sold shares: Director Julie Mchugh sold 21,571 shares, while insider Ronald Silver sold 127,890 shares. Corporate insiders retain a 9.30% ownership stake.
• Ironwood’s latest quarterly results slightly missed expectations, with EPS of $0.31 versus $0.32 forecast and revenue of $113.04 million versus $114.84 million expected. Analysts maintain a “Moderate Buy” consensus with a $6.23 price target, compared with the stock’s $4.05 opening price.

Dimensional Fund Advisors LP increased its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 529.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,082,055 shares of the biotechnology company's stock after purchasing an additional 1,751,219 shares during the period. Dimensional Fund Advisors LP owned 1.28% of Ironwood Pharmaceuticals worth $7,307,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Integrated Wealth Concepts LLC increased its position in Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company's stock worth $25,000 after buying an additional 3,406 shares in the last quarter. LSV Asset Management acquired a new position in shares of Ironwood Pharmaceuticals in the fourth quarter worth $30,000. Captrust Financial Advisors purchased a new stake in shares of Ironwood Pharmaceuticals in the second quarter valued at $32,000. Jump Financial LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at $34,000. Finally, DGS Capital Management LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at $35,000.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, Director Julie Mchugh sold 21,571 shares of Ironwood Pharmaceuticals stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total value of $80,459.83. Following the transaction, the director owned 250,749 shares in the company, valued at $935,293.77. This trade represents a 7.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Ronald Silver sold 127,890 shares of the business's stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total transaction of $578,062.80. Following the sale, the insider directly owned 313,680 shares of the company's stock, valued at $1,417,833.60. This represents a 28.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 9.30% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on IRWD. Zacks Research cut Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 30th. Wall Street Zen lowered shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday. Finally, Weiss Ratings raised shares of Ironwood Pharmaceuticals from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $6.23.

Ironwood Pharmaceuticals Trading Down 6.3%

Shares of NASDAQ:IRWD opened at $4.05 on Tuesday. The firm has a market cap of $660.38 million, a price-to-earnings ratio of 5.26 and a beta of 0.20. The stock's 50-day moving average price is $3.91 and its two-hundred day moving average price is $3.96. Ironwood Pharmaceuticals, Inc. has a 12-month low of $0.81 and a 12-month high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.31 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.01). Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. The company had revenue of $113.04 million for the quarter, compared to analyst estimates of $114.84 million. As a group, research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.04 earnings per share for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company's flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source